Pioneering Precision: New Research Shows Rocket Science Health’s Laminar Fluid Ejection Device Leads in Therapeutic Drug Delivery
Author: Rocket Science Health
At Rocket Science Health (RSH), we are driven by a single mission: to transform healthcare through precision drug delivery technologies focused on brain-targeted therapies and vaccines. In pursuit of this, we have developed our proprietary Laminar Fluid Ejection (LFE) technology to meet a critical challenge in neuroscience—delivering therapeutics effectively to the brain.
We are excited to announce that our device was evaluated in a recent study exploring the efficacy of intranasal delivery systems for vaccines. The findings demonstrate potential advantages of the Rocket Science device for the delivery of certain advanced therapeutics.
Breakthrough Study: LFE Device Outperforms Conventional Methods
In a new peer-reviewed study, Laminar fluid ejection device enables high yield and preservation of mRNA and SaRNA LNP formulations from Scientific Reports (a Nature portfolio journal) the Blakney Lab at UBC assessed vaccine formulation with three intranasal delivery devices: a commercial nebulizer, a standard nasal spray, and Rocket Science Health’s LFE device.
The researchers aimed to assess each device’s ability to:
• Maintain the structural integrity of the vaccine
• Deliver the intended dose, and
• Preserve the biological activity of the vaccine after administration.
Key Findings: LFE Preserves Delicate Molecules
Rocket Science Health’s LFE device outperformed the alternatives by best preserving the lipid nano particle structural integrity – ensuring it remains fully effective – and minimizing waste by delivering the highest proportion of active vaccine to its intended target.
Why it Matters
The study’s findings highlight a critical point: the way a therapy is delivered can be just as important as what’s in the vial. For researchers, these results shed light on the pitfalls of conventional intranasal delivery systems. For Rocket Science Health, the findings are a strong validation of our vision and innovation.
The LFE system’s exceptional performance in protecting and delivering therapeutics is a pivotal step in revolutionizing brain and CNS disorder treatment. These results build upon prior research showing that drug deposition to the olfactory cleft (which the LFE device targets) is a viable pathway for reaching the CNS.
We now have strong evidence that our LFE technology can deliver therapeutics with both high accuracy and efficiency—bringing us one step closer to making a real difference in brain and CNS healthcare.
What’s Next for Rocket Science Health?
With this exciting research and our recently announced partnership with Kindeva—a global leader in drug-device development and manufacturing—we’re accelerating the scale-up and clinical validation of our LFE device.
As we move forward, we’re looking to expand our LFE technology into areas with the greatest need—from mental health to neurodegeneration. We invite pharmaceutical, biotech, and research organizations that share our vision of advancing brain and CNS therapeutics to partner with us.
